Stoke Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Stoke Therapeutics Inc (STOK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Stoke Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 28M vs 28,616M combined for tracked competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+35.2% annualized vs trailing 12 months), vs accelerating (+4.7%) for its tracked peer group.
- Growth: Stoke Therapeutics Inc generated -32.5% revenue growth year over year in Q2 2026, vs 13.7% for its tracked competitors combined.
- Profitability: Its -660.8% net margin compares with 17.2% for the peer group.
- Scale: Stoke Therapeutics Inc ranks #118 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Stoke Therapeutics Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.2% a year earlier.
- Peer differentiation: Revenue per employee of $0.16M compares with $1.32M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
STOK Sales vs. its Competitors, Q2 2026
Stoke Therapeutics Inc reported revenue contraction of 32.51 % year on year in Q2 2026, below its competitors' combined revenue growth of 13.72 %.
With a net margin of -660.78 %, Stoke Therapeutics Inc reported lower profitability than its competitors (17.24 %).
Stoke Therapeutics Inc generated 0.12 % of the combined sales of its peer group, down from 0.21 % a year earlier.
Stoke Therapeutics Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Stoke Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Stoke Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (2) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Stoke Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -32.5% for Stoke Therapeutics Inc. Stoke Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Stoke Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Stoke Therapeutics Inc | No | No | No | No |
| Competitors combined (28) | ||||
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) | 25.00 % (2 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
STOK Stock Performance relative to its Competitors
STOK Stock Performance relative to High-Confidence Competitors
STOK Stock Performance relative to Similar-Size Competitors
STOK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Regulus Therapeutics Inc | 282.9% | Outperformed |
| 2 | Apellis Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Silence Therapeutics Plc | 282.9% | Outperformed |
| 4 | Arrowhead Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Kalvista Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Stoke Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Stoke Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Stoke Therapeutics Inc | 1,683.46 | 27.59 |
| Regeneron Pharmaceuticals Inc | 79,738.50 | 15,534.70 |
| Alnylam Pharmaceuticals Inc | 35,311.44 | 4,804.18 |
| United Therapeutics Corporation | 22,237.73 | 3,154.50 |
| Arrowhead Pharmaceuticals Inc | 9,385.52 | 669.50 |
| Pharming Group N v | 7,857.03 | 375.63 |
| SUBTOTAL | 185,971.01 | 38,714.26 |
Sign in to see all competitors of Stoke Therapeutics Inc .
Sources: Stoke Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Stoke Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Stoke Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ovid Therapeutics Inc | Named by the company | 85% |
| Encoded Therapeutics | Named by the company | 85% |
| Zogenix | Named by the company | 85% |
| Camp4 Therapeutics Corporation | Named by the company | 85% |
| GW Pharmaceuticals, plc | Named by the company | 85% |
| Praxis Precision Medicines Inc | Named by the company | 85% |
| Crispr Therapeutics Ag | Named by the company | 85% |
| Xenon Pharmaceuticals | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Stoke Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Stoke Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ionis Pharmaceuticals Inc | Ionis Operations 100.00 % |
| Ptc Therapeutics inc | Life Science Segment 100.00 % |
| Apellis Pharmaceuticals Inc | Reportable Segment Aggregation Before Other Operating Segment 100.00 % |
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
| Lexicon Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Stoke Therapeutics Inc .
Stoke Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Stoke Therapeutics Inc | 1,683 | 162,282 | -1,222,953 |
| Regeneron Pharmaceuticals Inc | 79,739 | 1,008,092 | 280,902 |
| Alnylam Pharmaceuticals Inc | 35,311 | 1,921,673 | 323,195 |
| United Therapeutics Corporation | 22,238 | 2,253,214 | 936,357 |
| Arrowhead Pharmaceuticals Inc | 9,386 | 941,624 | -382,736 |
| Pharming Group N v | 7,857 | 1,859,574 | 12,564 |
| PEERS TOTAL | 184,288 | 1,322,486 | 163,788 |
Sign in to see all peers for Stoke Therapeutics Inc .
Stoke Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| United Therapeutics Corporation | UNITED STATES 95.23 % |
| Ptc Therapeutics inc | All Other Countries Other Than Russia Brazil and United States 16.36 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Stoke Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Stoke Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Stoke Therapeutics Inc ranks #118 of 498 companies by market capitalization in its industry, holding 0.03 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 823, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,058,838 | 19.26 % |
| 2 | Johnson and Johnson | 663,585 | 12.07 % |
| 3 | Beone Medicines Ltd | 552,468 | 10.05 % |
| 4 | Abbvie Inc | 471,582 | 8.58 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 118 | Stoke Therapeutics Inc | 1,683 | 0.03 % |
Market cap and industry share for the rest of Stoke Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Stoke Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 113 | Pharvaris N v | 1,745 | 28.76 % |
| 114 | Omeros Corporation | 1,741 | 356.39 % |
| 115 | Zenas Biopharma Inc | 1,739 | 43.05 % |
| 116 | Ocular Therapeutix Inc | 1,722 | -30.39 % |
| 117 | Xeris Biopharma Holdings Inc | 1,234 | 12.3% |
| 118 | Stoke Therapeutics Inc | 1,683 | 5.66 % |
| 119 | Ani Pharmaceuticals Inc | 1,234 | 12.3% |
| 120 | Syndax Pharmaceuticals Inc | 1,234 | 12.3% |
| 121 | Rapport Therapeutics Inc | 1,234 | 12.3% |
| 122 | Silence Therapeutics Plc | 1,234 | 12.3% |
| 123 | Innoviva Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Stoke Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Stoke Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 64.89 % (avg) | - |
| Operating Margin | -809.69 % | industry median | -756.0 pp |
| EBITDA Margin | -750.97 % | -7.21 % (avg) | -743.8 pp |
| Capital Intensity (Capex / Revenue) | 9.76 % | 4.92 % (avg) | +4.8 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Stoke Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 5.8x | 4.5x | +1.3x |
| Return on Equity | -59.36 % | industry aggregate | -76.61 % |
| Return on Invested Capital | -30.93 % | -2.95 % (avg) | -27.98 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Stoke Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | -29.22 % | 316.34 % | 404.50 % |
| Operating Margin | - | - | - | -841.24 % | -1,307.21 % | -277.31 % | -11.16 % |
| Return on Invested Capital | - | -11.81 % | -17.43 % | -22.04 % | -28.09 % | -23.14 % | -2.93 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Stoke Therapeutics Inc's Strategic Group Map
Every company in Stoke Therapeutics Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Stoke Therapeutics Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Stoke Therapeutics Inc's BCG Growth-Share Matrix
Relative market share (vs Stoke Therapeutics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Stoke Therapeutics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Stoke Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 823 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 9.76 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Stoke Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Stoke Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Stoke Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Stoke Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Stoke Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+35.2% annualized vs trailing 12 months).
Weaknesses
- Operating margin 756.0 points below the industry median.
- Return on equity 76.6 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (33.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Stoke Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Stoke Therapeutics Inc | 2.38 | 6.95 | - |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Alnylam Pharmaceuticals Inc | 1.12 | 2.86 | 1.18 |
| United Therapeutics Corporation | 2.58 | 5.86 | - |
| Arrowhead Pharmaceuticals Inc | 0.00 | 5.58 | 1.06 |
| Pharming Group N v | 1.25 | 2.59 | - |
Sign in to see all peers for Stoke Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Stoke Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Stoke Therapeutics Inc | Q2 2026 | -32.5 % | - |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +66.9 % | - |
| United Therapeutics Corporation | Q2 2026 | -1.9 % | +7.6 % |
| Arrowhead Pharmaceuticals Inc | Q2 2026 | +171.0 % | - |
| Pharming Group N v | Q4 2025 | +26.6 % | - |
| PEERS TOTAL | +12.1 % | +72.6 % |
Sign in to see all peers for Stoke Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Stoke Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Stoke Therapeutics Inc | Q2 2026 | - | +1,183.1 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Alnylam Pharmaceuticals Inc | Q2 2026 | +110.0 % | +142.6 % |
| United Therapeutics Corporation | Q2 2026 | +13.6 % | +73.6 % |
| Arrowhead Pharmaceuticals Inc | Q2 2026 | - | +63.0 % |
| Pharming Group N v | Q4 2025 | +35.1 % | -5.2 % |
Sign in to see all peers for Stoke Therapeutics Inc .
Stoke Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Stoke Therapeutics Inc | - | - | - |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Alnylam Pharmaceuticals Inc | 15.76% | 22.10% | 93.61% |
| United Therapeutics Corporation | 17.98% | 19.53% | 20.18% |
| Arrowhead Pharmaceuticals Inc | - | - | - |
| Pharming Group N v | 0.51% | 0.88% | 0.92% |
Sign in to see all peers for Stoke Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Stoke Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Stoke Therapeutics Inc | - | 61.02 |
| Regeneron Pharmaceuticals Inc | 18.63 | 5.13 |
| Alnylam Pharmaceuticals Inc | 45.20 | 7.35 |
| United Therapeutics Corporation | 17.43 | 7.05 |
| Arrowhead Pharmaceuticals Inc | - | 14.02 |
| Pharming Group N v | - | 20.92 |
| PEERS AVERAGE | 40.58 | 4.80 |
Sign in to see all peers for Stoke Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.